A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Effective treatments for alcohol dependence exist; however, they remain underused and are not effective, or suitable, for all ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

"In the case of oral semaglutide for overweight/obesity, it appears that 25 mg a day is that dose." The trial enrolled 243 participants with a BMI of at least 30, or 27 with a weight-related ...

In 2021, the FDA approved of another injectable semaglutide, Wegovy, for chronic weight management in adults with obesity/overweight and with at least one weight-related condition (such as high ...

For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.